SGLT-2-Inhibitoren – Eine Standortbestimmung in der deutschen oralen Therapielandschaft für Menschen mit Typ-2-Diabetes

Zusammenfassung

Wie aus zahlreichen umfangreichen Studien hervorgeht, haben SGLT-2-Inhibitoren nicht nur positive Effekte auf den Glukosestoffwechsel, sondern darüber hinaus eine ausgeprägte protektive Wirkung auf Herz und Nieren. Damit kommt dieser Wirkstoffklasse eine wichtige Rolle in der Primär- und Sekundärprävention diabetes-assoziierter Komorbiditäten zu. Leitlinien sprechen auf Basis der Evidenz für SGLT-2-Inhibitoren eine Empfehlung für deren frühen Einsatz bei Menschen mit Typ-2-Diabetes und gleichzeitigem hohen Risiko für kardiovaskuläre und/oder renale Ereignisse aus. Verordnungszahlen zeigen jedoch, dass diese Empfehlungen aktuell nicht umgesetzt werden und deutlich mehr Menschen mit Typ-2-Diabetes von einer organprotektiven Therapie profitieren könnten. Daher soll in dieser Übersichtsarbeit der Stellenwert der SGLT-2-Inhibitoren im Vergleich zu anderen oralen Therapieansätzen für die Behandlung des Typ-2-Diabetes dargestellt werden.

Abstract

As numerous extensive studies have shown, SGLT2 inhibitors not only have beneficial effects on glucose metabolism, but also have a pronounced protective effect on the heart and kidneys. This class of drugs therefore plays an important role in the primary and secondary prevention of diabetes-associated comorbidities. Based on the evidence for SGLT2 inhibitors, guidelines recommend their early use in people with type 2 diabetes being at high risk of cardiovascular and/or renal events. However, prescription data show that these recommendations are currently not implemented and that significantly more people with type 2 diabetes could benefit from organ-protective therapy. Therefore, the aim of this review is to present the value of SGLT2 inhibitors in comparison to other oral therapeutic approaches for the treatment of type 2 diabetes.

Schlüsselwörter

SGLT-2 - Typ-2-Diabetes - Therapie - Prävention - Vergleich

Keywords

SGLT2 - type 2 diabetes - therapy - prevention - comparison

Publication History

Received: 13 August 2024

Accepted after revision: 07 October 2024

Article published online:
16 December 2024

• Literatur

• 1 Deutsche Diabetes Gesellschaft (DDG). Deutscher Gesundheitsbericht Diabetes 2024 (14.11.2023). Accessed July 30, 2024 at: https://www.ddg.info/fileadmin/user_upload/Gesundheitsbericht_2024_Endversion.pdf
• 2 Tönnies T, Röckl S, Hoyer A. et al. Projected number of people with diagnosed Type 2 diabetes in Germany in 2040. Diabetic Medicine 2019; 36: 1217-1225
• 3 Bongaerts B, Kollhorst B, Kuss O. et al. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2022; 130: 587-595
• 4 Wilke T, Picker N, Mueller S. et al. Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019; 12: 1225-1237
• 5 Barth SD, Kostev K, Krensel M. et al. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2023; 131: 153-161
• 6 Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London, England) 2022; 400: 1788-1801
• 7 Vaduganathan M, Docherty KF, Claggett BL. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet (London, England) 2022; 400: 757-767
• 8 Dal Canto E, Ceriello A, Ryden L. et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26: 25-32
• 9 Ene-Iordache B, Perico N, Bikbov B. et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health 2016; 4: e307-319
• 10 Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic medicine : a journal of the British Diabetic Association 2010; 27: 136-142
• 11 Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne) 2021; 8: 777861
• 12 Bakris GL, Fonseca VA, Sharma K. et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney international 2009; 75: 1272-1277
• 13 Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clinical journal of the American Society of Nephrology : CJASN 2021; 16: 1284-1291
• 14 Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature reviews Cardiology 2020; 17: 761-772
• 15 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung. 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014.
• 16 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung. Version 3.0. 2023
• 17 He G, Yang G, Huang X. et al. SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials. Heart Lung 2023; 59: 109-116
• 18 Zelniker TA, Wiviott SD, Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 2019; 393: 31-39
• 19 Mosenzon O, Raz I, Wiviott SD. et al. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care 2022; 45: 2350-2359
• 20 Fadini GP, Longato E, Morieri ML. et al. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk. Lancet Reg Health Eur 2024; 38: 100847
• 21 Wanner C, Inzucchi SE, Zinman B. et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism 2020; 22: 2335-2347
• 22 Ceriello A, Lucisano G, Prattichizzo F. et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Reg Health Eur 2023; 31: 100666
• 23 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine 2015; 373: 2117-2128
• 24 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine 2019; 380: 347-357
• 25 Cahn A, Raz I, Leiter LA. et al. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care 2021; 44: 1159-1167
• 26 McMurray JJV, Wheeler DC, Stefansson BV. et al. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation 2021; 143: 438-448
• 27 Feng M, Lv H, Xu X. et al. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine 2019; 98: e16575
• 28 McNeill AM, Davies G, Kruger E. et al. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 2019; 10: 473-491
• 29 Zhang F, Wang W, Hou X. Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials. J Diabetes Investig 2022; 13: 478-488
• 30 Xu X, Xu W, Zhuo Q. et al. The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis. Ann Palliat Med 2022; 11: 1028-1037
• 31 Zhang YJ, Han SL, Sun XF. et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials. Medicine 2018; 97: e12843
• 32 Liu L, Shi FH, Xu H. et al. Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front Pharmacol 2021; 12: 752440
• 33 Kudo A, Machii N, Ono T. et al. Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study. BMJ Open Diabetes Res Care 2023; 11
• 34 Bailey CJ, Gross JL, Hennicken D. et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43
• 35 Bailey CJ, Morales Villegas EC, Woo V. et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabetic medicine : a journal of the British Diabetic Association 2015; 32: 531-541
• 36 Roden M, Merker L, Christiansen AV. et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular diabetology 2015; 14: 154
• 37 Merker L, Haring HU, Christiansen AV. et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association 2015; 32: 1555-1567
• 38 Gallo S, Charbonnel B, Goldman A. et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes, obesity & metabolism 2019; 21: 1027-1036
• 39 Aronson R, Frias J, Goldman A. et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, obesity & metabolism 2018; 20: 1453-1460
• 40 Gu S, Hu X, Shi L. et al. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. J Clin Med 2022; 11
• 41 Qian D, Zhang T, Zheng P. et al. Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 2018; 9: 1945-1958
• 42 Collier A, Meney C, Hair M. et al. Cancer has overtaken cardiovascular disease as the commonest cause of death in Scottish type 2 diabetes patients: A population-based study (The Ayrshire Diabetes Follow-up Cohort study). J Diabetes Investig 2020; 11: 55-61
• 43 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. The lancet Diabetes & endocrinology 2021; 9: 165-173
• 44 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England journal of medicine 2017; 377: 644-657
• 45 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of medicine 2019; 380: 2295-2306
• 46 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine 2019; 381: 1995-2008
• 47 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England journal of medicine 2020; 383: 1413-1424
• 48 Heerspink HJL, Stefansson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine 2020; 383: 1436-1446
• 49 Bhatt DL, Szarek M, Pitt B. et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England journal of medicine 2021; 384: 129-139
• 50 Cannon CP, Pratley R, Dagogo-Jack S. et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The New England journal of medicine 2020; 383: 1425-1435
• 51 Bhatt DL, Szarek M, Steg PG. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England journal of medicine 2020; 384: 117-128
• 52 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine 2021;
• 53 Solomon SD, de Boer RA, DeMets D. et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European journal of heart failure 2021; 23: 1217-1225
• 54 Herrington WG, Staplin N. The EMPA-KIDNEY Collaborative Group. et al. Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine 2023; 388: 117-127
• 55 James S, Erlinge D, Storey RF. et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid 2024; 3: EVIDoa2300286
• 56 Butler J, Jones WS, Udell JA. et al. Empagliflozin after Acute Myocardial Infarction. The New England journal of medicine 2024; 390: 1455-1466
• 57 Schechter M, Wiviott SD, Raz I. et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. The lancet Diabetes & endocrinology 2023; 11: 233-241
• 58 Jhund PS, Kondo T, Butt JH. et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature medicine 2022; 28: 1956-1964
• 59 Butler J, Packer M, Filippatos G. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European heart journal 2022; 43: 416-426
• 60 Cosentino F, Cannon CP, Cherney DZI. et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation 2020; 142: 2205-2215
• 61 Khunti K, Kosiborod M, Kim DJ. et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular diabetology 2021; 20: 159
• 62 Heerspink HJL, Karasik A, Thuresson M. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. The lancet Diabetes & endocrinology 2020; 8: 27-35
• 63 Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism: clinical and experimental 2022; 130: 155160
• 64 Bergmark BA, Bhatt DL, McGuire DK. et al. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation 2019; 140: 1004-1014
• 65 Holman RR, Paul SK, Bethel MA. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine 2008; 359: 1577-1589
• 66 Vaccaro O, Masulli M, Nicolucci A. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The lancet Diabetes & endocrinology 2017; 5: 887-897
• 67 Rosenstock J, Kahn SE, Johansen OE. et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. Jama 2019; 322: 1155-1166
• 68 Maiorino MI, Longo M, Scappaticcio L. et al. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular diabetology 2021; 20: 210
• 69 Giugliano D, Longo M, Signoriello S. et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovascular diabetology 2022; 21: 42
• 70 Qiu M, Ding LL, Zhang M. et al. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diabetes & vascular disease research 2021; 18: 14791641211011016
• 71 Kalra S, Baruah MP, Sahay R. Medication counselling with sodium glucose transporter 2 inhibitor therapy. Indian J Endocrinol Metab 2014; 18: 597-599
• 72 Williams SM, Ahmed SH. 1224-P: Improving Compliance with SGLT2 Inhibitors by Reducing the Risk of Genital Mycotic Infections: The Outcomes of Personal Hygiene Advice. Diabetes 2019; 68
• 73 Chowdhury T, Gousy N, Bellamkonda A. et al. Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy. Cureus 2022; 14: e27773
• 74 Ellegard L, Prytz M. Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report. Int J Surg Case Rep 2020; 77: 692-694
• 75 Leslie SW, Rad J, Foreman J. Fournier Gangrene. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024
• 76 Colacci M, Fralick J, Odutayo A. et al. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Canadian journal of diabetes 2022; 46: 10-15 e12
• 77 Arzneimittelkommission der deutschen Ärzteschaft. Atypische diabetische Ketoazidosen im Zusammenhang mit SGLT-2-Hemmern (Gliflozine). Deutsches Ärzteblatt 2018; 115.
• 78 Kietaibl AT, Huber J, Clodi M. et al. Position statement: surgery and diabetes mellitus (Update 2023). Wien Klin Wochenschr 2023; 135: 256-271
• 79 Schütt K, Aberle J, Bauersachs J. et al. Positionspapier Herzinsuffizienz und Diabetes. Die Kardiologie 2022; 16: 358-371
• 80 Nasa P, Chaudhary S, Shrivastava PK. et al. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes 2021; 12: 514-523
• 81 Hassanein M, Bashier A, Randeree H. et al. Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes research and clinical practice 2020; 169: 108465
• 82 Zaccardi F, Ling S, Lawson C. et al. Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia 2020; 63: 2129-2139
• 83 Hougen I, Whitlock RH, Komenda P. et al. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study. BMJ Open Diabetes Res Care 2021; 9
• 84 Volke V, Katus U, Johannson A. et al. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. BMC endocrine disorders 2022; 22: 251
• 85 Gemeinsamer Bundesausschuss (G-BA). Nutzenbewertung von Arzneimitteln. Accessed September 27, 2024 at: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/
• 86 Hellman M. SGLT2-Inhibitoren: fachmedizinische Aspekte aus hausärztlicher Sicht. Accessed September 27, 2024 at: https://www.esanum.de/conferences/der-internistenkongress/feeds/today/posts/sglt2-inhibitoren-hausaerzte
• 87 GKV-Spitzenverband. Anlage zur Vereinbarung nach § 130b Abs. 1 Satz 1 SGB V zwischen dem GKV-Spitzenverband und der Boehringer Ingelheim Pharma GmbH & Co. KG zum Arzneimittel Jardiance (Wirkstoff: Empagliflozin) bezüglich der Anerkennung einer Praxisbesonderheit. Accessed September 27, 2024 at: https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/amnog_praxisbesonderheiten/14034pb20170301.pdf
• 88 GKV-Spitzenverband. Anlage zur Vereinbarung nach § 130b Abs. 1 Satz 1 SGB V zwischen dem GKV-Spitzenverband und der AstraZeneca GmbH zum Arzneimittel Forxiga® (Wirkstoff: Dapagliflozin) bezüglich der Anerkennung einer Praxisbesonderhei. Accessed September 27, 2024 at: https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/amnog_praxisbesonderheiten/13016pb20230113.pdf
• 89 Morieri ML, Longato E, Di Camillo B. et al. Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care. Cardiovascular diabetology 2022; 21: 274
• 90 Boonman-de Winter LJ, Rutten FH, Cramer MJ. et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012; 55: 2154-2162
• 91 Tangri N, Moriyama T, Schneider MP. et al. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ open 2023; 13: e067386
• 92 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international 2024; 105: S117-S314
• 93 McDonagh TA, Metra M, Adamo M. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal 2023; 44: 3627-3639